Lapchak P A, Araujo D M, Hefti F
Division of Neurogerontology, Andrus Gerontology Center, University of Southern California, Los Angeles 90089-0191.
Neuroscience. 1993 Mar;53(2):379-94. doi: 10.1016/0306-4522(93)90202-q.
Effects of chronic intraventricular administration of recombinant human nerve growth factor on hippocampal muscarinic receptor densities and muscarinic receptor-linked second messenger systems were determined in adult rats 21 days following partial or full unilateral fimbrial transections. First, autoradiographic analysis of muscarinic receptors was carried out using [3H]quinuclidinyl benzilate for total muscarinic receptors, [3H]pirenzepine for M1 receptors and [3H]AF-DX 384 for M2 receptors. Partial fimbrial transections did not significantly alter the density of these muscarinic receptor populations in the dorsal or ventral hippocampus and there was no effect of chronic (1 micrograms every other day, 21 days) recombinant human nerve growth factor treatment. In contrast, in animals receiving full fimbrial transections which by themselves did not alter muscarinic receptor density, recombinant human nerve growth factor treatment increased the density of [3H]quinuclidinyl benzilate binding sites, M1 receptors, and M2 receptors by approximately 40% in the CA1 region. Secondly, we determined the effect of chronic recombinant human nerve growth factor treatment on muscarinic receptor-mediated second messenger production in rats with either partial or full unilateral fimbrial transections. In partially fimbriectomized rats, oxotremorine-induced inositol triphosphate production by hippocampal slices was increased by 81% on the lesioned side of animals treated with a control protein. This lesion-induced supersensitivity of M1 muscarinic receptor function was prevented by chronic recombinant human nerve growth factor treatment. In recombinant human nerve growth factor-treated animals, inositol triphosphate production was similar to values on unlesioned control sides. The muscarinic receptor-mediated increase in cyclic GMP levels was not altered by fimbrial transections or recombinant human nerve growth factor treatment. In animals with full unilateral fimbrial transections, oxotremorine-induced inositol triphosphate production was increased by 99% on the lesioned side of animals treated with a control protein and treatment with recombinant human nerve growth factor did not alter this denervation-induced supersensitivity of muscarinic receptor transduction signal. Chronic recombinant human nerve growth factor treatment did not affect the levels of inositol triphosphate on the contralateral unlesioned side of either partial or full fimbriectomized animals. Earlier studies indicate that chronic nerve growth factor treatment increases the presynaptic function of hippocampal cholinergic neurons surviving partial fimbrial transections. The findings of the present study indicate that these presynaptic effects translate into functional changes at the level of postsynaptic muscarinic receptors in the hippocampus.(ABSTRACT TRUNCATED AT 400 WORDS)
在成年大鼠单侧部分或完全穹窿横断21天后,测定慢性脑室内注射重组人神经生长因子对海马毒蕈碱受体密度和毒蕈碱受体相关第二信使系统的影响。首先,使用[3H]喹核醇基苯甲酸酯检测总毒蕈碱受体、[3H]哌仑西平检测M1受体以及[3H]AF-DX 384检测M2受体,对毒蕈碱受体进行放射自显影分析。部分穹窿横断并未显著改变背侧或腹侧海马中这些毒蕈碱受体群体的密度,慢性(每隔一天1微克,共21天)重组人神经生长因子治疗也无影响。相比之下,在接受完全穹窿横断的动物中(其本身未改变毒蕈碱受体密度),重组人神经生长因子治疗使CA1区[3H]喹核醇基苯甲酸酯结合位点、M1受体和M2受体的密度增加了约40%。其次,我们测定了慢性重组人神经生长因子治疗对单侧部分或完全穹窿横断大鼠中毒蕈碱受体介导的第二信使产生的影响。在部分穹窿切除的大鼠中,用对照蛋白处理的动物损伤侧海马切片中,氧化震颤素诱导的肌醇三磷酸产生增加了81%。慢性重组人神经生长因子治疗可防止这种由损伤诱导的M1毒蕈碱受体功能超敏反应。在重组人神经生长因子处理的动物中,肌醇三磷酸产生与未损伤对照侧的值相似。毒蕈碱受体介导的环鸟苷酸水平升高不受穹窿横断或重组人神经生长因子治疗的影响。在单侧完全穹窿横断的动物中,用对照蛋白处理的动物损伤侧氧化震颤素诱导的肌醇三磷酸产生增加了99%,重组人神经生长因子治疗并未改变这种由去神经支配诱导的毒蕈碱受体转导信号超敏反应。慢性重组人神经生长因子治疗对部分或完全穹窿切除动物对侧未损伤侧的肌醇三磷酸水平无影响。早期研究表明,慢性神经生长因子治疗可增强部分穹窿横断后存活的海马胆碱能神经元的突触前功能。本研究结果表明,这些突触前效应转化为海马突触后毒蕈碱受体水平的功能变化。(摘要截断于400字)